RGC Resources, Inc. Announces Common Stock Offering
Mar 14, 2018 20:09 pm UTC| Business
ROANOKE, Va., March 14, 2018 -- RGC Resources, Inc. (NASDAQ: RGCO) announced today the commencement of an underwritten public offering of its common stock with an aggregate value of approximately $14,000,000. In...
Novavax Provides Corporate Update and Report of Fourth Quarter and Year-End 2017 Financial Results
Mar 14, 2018 20:08 pm UTC| Business
RSV Phase 3 Prepare™ Trial Outcome De-risked by Successful Informational AnalysisNanoFlu™ Vaccine Demonstrates Improved Immune Responses Compared to Egg-Based, High-Dose Flu VaccineJohn J. Trizzino Appointed Chief Business...
Rubicon Project Reports Fourth Quarter and Full Year 2017 Results
Mar 14, 2018 20:06 pm UTC| Business
LOS ANGELES, March 14, 2018 -- Rubicon Project (NYSE:RUBI), the global exchange for advertising, today reported its results of operations for the fourth quarter and year ended December 31, 2017. Recent Highlights: ...
Benefitfocus Announces Fourth Quarter and Full Year 2017 Financial Results
Mar 14, 2018 20:05 pm UTC| Business
2017 total revenue of $256.7 million grew 10% year-over-year2017 employer revenue of $164.0 million grew 17% year-over-year CHARLESTON, S.C., March 14, 2018 -- Benefitfocus, Inc. (NASDAQ:BNFT), a leading provider of...
Sunesis Pharmaceuticals to Present at Upcoming Investor Conferences
Mar 14, 2018 20:05 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., March 14, 2018 -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the Company will present at two upcoming investor conferences. Willie Quinn, Chief Financial Officer and...
Oxford to Release Fourth Quarter and Fiscal 2017 Results on March 28, 2018
Mar 14, 2018 20:05 pm UTC| Business
ATLANTA, March 14, 2018 -- Oxford Industries, Inc. (NYSE:OXM) will report its fiscal fourth quarter and fiscal year 2017 ended February 3, 2018 financial results on Wednesday, March 28, 2018 after the market close. The...
Mar 14, 2018 20:05 pm UTC| Business
Data from Phase 1 clinical trial supports advancing cobomarsen, or MRG-106, into a Phase 2 potentially registrational clinical trial for CTCL (the SOLAR trial)Completed Phase 1 clinical trial of MRG-201 supports...